Ahmed Mohammed Ahmed 于2010年毕业于苏丹奥姆杜尔曼伊斯兰大学，获得生物技术科学学士学位。 他在非洲技术城市（ACT）的苏丹科学院生物技术与生物信息学研究所在工业生物技术领域获得了理学硕士学位。 他的硕士学位论文的研究重点是疫苗学（与苏丹联邦卫生部合作进行的病例对照研究，以评估苏丹的PCV-13疫苗）。 2017年，他加入了金腾川教授的研究小组，从事蛋白质工程和蛋白质药物发现领域的研究项目。
晚期糖基化终产物的受体是模式识别受体，属于免疫球蛋白超家族。 这种与多种疾病的发展相关的RAGE，包括血管并发症，糖尿病，癌症，阿尔茨海默氏病以及受体寡聚化，似乎是形成活性信号复合物的关键参数，因为他的研究重点在于筛选新的抑制剂来阻断RAGE-配体相互作用。
Ahmed Mohammed Ahmed He graduated from Omdurman Islamic University (Sudan) in 2010 with a bachelor's degree in Science in biotechnology. He completed his M.Sc. in Science in the field of industrial biotechnology from Sudan Academy of Science in Africa City of Technology (ACT), institute of biotechnology and bioinformatics. his M.Sc. thesis study focused on Vaccinology (Case-control study to evaluate the PCV-13 vaccine in Sudan collaborated with the ministry of federal health of Sudan). In 2017, he joined the research group of Professor Jin Tengchuan to conduct research, in the field of protein engineering and protein drug discovery
A brief introduction to his Ph.D. project.
The receptor for advanced glycation end products, is a pattern-recognition receptor belong to immunoglobulin superfamily. RAGE associated with the development of various diseases including Vascular complications, Diabetes, Cancer, Alzheimer’s disease, and also Receptor oligomerization appears to be a crucial parameter for the formation of active signaling complexes, for that his research focuses on screening for novel inhibitors to block RAGE-Ligands interaction.
Representative papers
Mengist, Hylemariam Mihiretie, Daniel Mekonnen, Ahmed Mohammed, Ronghua Shi, and Tengchuan Jin. "Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease." Frontiers in pharmacology 11 (2021): 2495.
Zeng, Weihong, Guangfeng Liu, Huan Ma, Dan Zhao, Yunru Yang, Muziying Liu, Ahmed Mohammed et al. "Biochemical characterization of SARS-CoV-2 nucleocapsid protein." Biochemical and biophysical research communications 527, no. 3 (2020): 618-623.
